摘要
目的探讨阿帕替尼联合化疗治疗晚期胃癌的临床疗效及预后。方法选取2014年12月至2016年12月间江苏省肿瘤医院收治的64例晚期胃癌患者,其中采用阿帕替尼联合化疗治疗的34例患者为观察组,仅进行化疗治疗的30例患者为对照组。两组患者化疗方案均为5-氟尿嘧啶(5-Fu)、奥沙利铂和亚叶酸钙(FOLFOX6方案)。随访至2017年5月,统计两组患者的临床疗效、生存时间和不良反应发生情况。结果观察组和对照组患者总缓解率分别为52.9%和26.7%,疾病控制率分别为88.2%和50.0%,两组比较,差异均有统计学意义(均P<0.05)。观察组患者无进展生存时间和总生存时间均显著高于对照组,差异均有统计学意义(均P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论阿帕替尼耐受性较好,在化疗基础上联合阿帕替尼能显著提高晚期胃癌的临床疗效,延长患者的生存时间,且安全可靠,值得临床推荐。
Objective To investigate the clinical efficacy and prognosis of apatinib combined with chemotherapy in the treatment of advanced gastric cancer. Methods The clinical data of 64 patients with advanced gastric cancer who received apatinib combined with chemotherapy from December 2014 to December 2016 at Jiangsu Cancer Hospital were enrolled and analyzed retrospectively. Among them,34 patients receiving apatinib combined with chemotherapy were included in the observation group and 30 patients receiving single chemotherapy were included in the control group. Both groups received fluorouracil（ 5-Fu）,oxaplatin（ OXA） and L-calcium levofolinate（ LV）（ FOLFOX-6） based chemotherapy. Apart from this,the observation group also received oral apatinib. Outpatient were followed-up until May 2017. The clinical efficacy,survival time and the adverse reactions were compared between the two groups. Results The overall remission rate was 50. 9% and 26. 7% respectively and the control rate was 88. 2% and 50. 0% respectively for the observation group and the control group（ all P〈0. 05）. The progression-free survival and overall survival were significantly higher in the observation group than in the control group（ all P〈0. 05）.There was no significant difference in the incidence of adverse reactions between the two groups（ P〉0. 05）. Conclusion Apatinib is well tolerated and the combination therapy of apatinib with chemotherapy can significantly improve the clinical efficacy and prolong the survival time in patients with advanced gastric cancer and it is safe and reliable and is worthy of clinical recommendation.
出处
《中国肿瘤临床与康复》
2018年第1期44-46,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
江苏省肿瘤医院科研立项(ANIMATE-JS-205)
关键词
胃肿瘤
阿帕替尼
药物疗法
Gastric neoplasms
Apatinib
Drug therapy
